AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin of 61.4%, an increase of 16.1 percentage points from the same six-month period in 2020; and the average selling price of CDA-based tests being $71, also an increase over last year’s average price for the same period. The company also reported a decrease in non-GAAP net loss of more than 18% with this year’s total being $5.8 million. Corporate highlights included continued validation regarding the efficacy of CDA testing provided through clinical study follow-ups. In addition, the company has completed development and evaluation of a second-generation cancer detection sensor. “We are very pleased with the significant increases in our revenue and commercial cancer testing volume in the first half year, which are strong indications that AnPac Bio’s technology, services and quality are being recognized by the market and gaining traction,” said AnPac Bio chair and CEO Chris Yu in the press release. “Overall, our company is heading in the right direction. . . . We are fully committed to innovating and developing new products and technologies and working closely with customers to achieve continued growth.”
To view the full press release, visit https://ibn.fm/q9XxR
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
